Clinical Evaluation of Pit and Fissure Sealants Placed by Intern Dental Students After Tele-Demonstration Technique.

Eur J Dent EducApr 27, 2026 (epub)
Clinical ResearchPediatrics

Ahmed El-Sebaai, Kareem Hamdi, Nasr Mohamed Attia

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial compared pit and fissure sealants placed by dental interns after direct clinical demonstration or tele-education using a pre-recorded video. The split-mouth study included 100 mandibular first permanent molars in 50 children aged 7 to 9 years. At 3 months, sealant retention and marginal discolouration did not differ significantly between training groups (p = 0.766 and p = 1.000, respectively). The tele-education group had a slightly higher relative risk, which the authors judged not clinically significant.

Key findings

  • Sealant retention showed no statistically significant difference between direct demonstration and tele-education (p = 0.766).
  • Marginal discolouration did not differ significantly between groups (p = 1.000).
  • The tele-education group had a slightly higher relative risk, but the difference was not clinically significant.

Why it matters

The findings suggest that a pre-recorded tele-demonstration can support intern training in a preventive dental procedure without an observed short-term disadvantage in sealant retention or marginal discolouration. This is relevant to educational settings considering remote instructional tools, while the results concern a specific procedure, trainee group, and follow-up period.

What to keep in mind

Outcomes were assessed after only 3 months, so the study does not establish longer-term sealant performance.

Source

Published in Eur J Dent Educ. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.